BCL2L1 and neoplasm: Data analysis yielded five drugs that emerged as potential candidates due to their superior efficacy in tumor cells: paclitaxel, d-actinomycin, volasertib (PLK1 inhibitor), navitoclax (BCL-2/BCL-XL/BCL-w inhibitor) and I-BET-151 (a Bromodomain family inhibitor) (Supplementary Fig. 5a, online resource).